Retrospective analysis of hospital-acquired linezolid-nonsusceptible enterococci infection in Chongqing, China, 2011-2014

Published:August 25, 2015DOI:


      • We found transferring from another hospital was a unique independent predictor for acquiring linezolid-nonsusceptible enterococci.
      • Our findings suggest that gallbladder disease was significantly associated with linezolid-susceptible enterococci infection.
      • Polymicrobial infection was the only factor identified in both linezolid-nonsusceptible and linezolid-susceptible enterococci groups compared with controls; however, there was no significant difference between linezolid-nonsusceptible and linezolid-susceptible enterococci groups.
      • We found there was no statistical significance between cases and controls with respect to in-hospital mortality.


      Linezolid-nonsusceptible enterococci (LNSE) is an increasingly emerging multidrug-resistant pathogen, and the caused nosocomial infections are difficult to manage. However, data on the host-related risk factors and clinical outcomes for LNSE infection are poorly characterized.


      A retrospective case-case-control study of risk factors and clinical outcomes of hospitalized patients with LNSE infection during the period 2011-2014 was conducted in a teaching hospital in Chongqing, China. Case patients with LNSE and those with linezolid-susceptible enterococci (LSE) and controls with no enterococcal infection were compared at a ratio of 1:1:4. Two parallel multivariate logistic regression models were used to evaluate independent predictors for acquiring LNSE and LSE, respectively.


      Forty-four LNSE cases, 44 LSE cases, and 176 uninfected controls were analyzed. Multivariable analysis indicated that transferring from another hospital (odds ratio [OR], 3.57; 95% confidence interval [CI], 1.58-8.09), peripheral vascular disease (OR, 4.36; 95% CI, 1.64-11.60), and exposure to cephalosporins (OR, 4.24; 95% CI, 1.85-9.71) were unique independent predictors for acquiring LNSE. Gallbladder disease (OR, 3.64; 95% CI, 1.36-9.74) was independently associated with LSE acquisition. Polymicrobial infection was the only factor identified in both LNSE and LSE groups compared with controls; however, no statistical significance was observed in in-hospital mortality.


      Timely control efforts and appropriate antibiotic stewardship programs are necessary to effectively reduce the burden of LNSE infections among high-risk patients.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shaw K.J.
        • Barbachyn M.R.
        The oxazolidinones: past, present, and future.
        Ann N Y Acad Sci. 2011; 1241: 48-70
        • Long K.S.
        • Vester B.
        Resistance to linezolid caused by modifications at its binding site on the ribosome.
        Antimicrobial Agents Chemother. 2012; 56: 603-612
        • Mendes R.E.
        • Hogan P.A.
        • Streit J.M.
        • Jones R.N.
        • Flamm R.K.
        Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12).
        J Antimicrob Chemother. 2014; 69: 1582-1588
        • Mendes R.E.
        • Flamm R.K.
        • Hogan P.A.
        • Ross J.E.
        • Jones R.N.
        Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.
        Antimicrobial Agents Chemother. 2014; 58: 1243-1247
        • McGregor J.C.
        • Hartung D.M.
        • Allen G.P.
        • Taplitz R.A.
        • Traver R.
        • Tong T.
        • et al.
        Risk factors associated with linezolid-nonsusceptible enterococcal infections.
        Am J Infect Control. 2012; 40: 886-887
        • Santayana E.M.
        • Grim S.A.
        • Janda W.M.
        • Layden J.E.
        • Lee T.A.
        • Clark N.M.
        Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid.
        Diagn Microbiol Infect Dis. 2012; 74: 39-42
        • Pai M.P.
        • Rodvold K.A.
        • Schreckenberger P.C.
        • Gonzales R.D.
        • Petrolatti J.M.
        • Quinn J.P.
        Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium.
        Clin Infect Dis. 2002; 35: 1269-1272
        • Hayakawa K.
        • Marchaim D.
        • Pogue J.M.
        • Ho K.
        • Parveen S.
        • Nanjireddy P.
        • et al.
        Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study.
        Am J Infect Control. 2012; 40: 261-263
        • Pogue J.M.
        • Paterson D.L.
        • Pasculle A.W.
        • Potoski B.A.
        Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus.
        Infect Control Hosp Epidemiol. 2007; 28: 1382-1388
        • Kaye K.S.
        • Harris A.D.
        • Samore M.
        • Carmeli Y.
        The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance.
        Infect Control Hosp Epidemiol. 2005; 26: 346-351
      1. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 10th ed. CLSI document M07–A10. Wayne [PA]: CLSI, 2014.

      2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 23th informational supplement. CLSI document M100–S20. Wayne [PA]: CLSI, 2014.

        • Garner J.S.
        • Jarvis W.R.
        • Emori T.G.
        • Horan T.C.
        • Hughes J.M.
        CDC definitions for nosocomial infections, 1988.
        Am J Infect Control. 1988; 16: 128-140
        • Katz S.
        • Ford A.B.
        • Moskowitz R.W.
        • Jackson B.A.
        • Jaffe M.W.
        Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function.
        JAMA. 1963; 185: 914-919
        • Lodise T.P.
        • McKinnon P.S.
        • Tam V.H.
        • Rybak M.J.
        Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center.
        Clin Infect Dis. 2002; 34: 922-929
        • Onderdonk A.B.
        • Bartlett J.G.
        • Louie T.
        • Sullivan-Seigler N.
        • Gorbach S.L.
        Microbial synergy in experimental intra-abdominal abscess.
        Infect Immun. 1976; 13: 22-26
        • Korgaonkar A.
        • Trivedi U.
        • Rumbaugh K.P.
        • Whiteley M.
        Community surveillance enhances Pseudomonas aeruginosa virulence during polymicrobial infection.
        Proc Natl Acad Sci U S A. 2013; 110: 1059-1064
        • Murray J.L.
        • Connell J.L.
        • Stacy A.
        • Turner K.H.
        • Whiteley M.
        Mechanisms of synergy in polymicrobial infections.
        J Microbiol. 2014; 52: 188-199
        • Leung J.W.
        • Liu Y.L.
        • Desta T.
        • Libby E.
        • Inciardi J.F.
        • Lam K.
        Is there a synergistic effect between mixed bacterial infection in biofilm formation on biliary stents?.
        Gastrointest Endosc. 1988; 48: 250-257
        • Speer A.G.
        • Cotton P.B.
        • Rode J.
        • Seddon A.M.
        • Neal C.R.
        • Holton J.
        • et al.
        Biliary stent blockage with bacterial biofilm.
        Ann Intern Med. 1988; 108: 546-553
        • Leung J.W.
        • Ling T.K.
        • Chan R.C.
        • Cheung S.W.
        • Lai C.W.
        • Sung J.J.
        • et al.
        Antibiotics, biliary sepsis and bile duct stones.
        Gastrointest Endosc. 1994; 40: 716-721
        • Pallares R.
        • Pujol M.
        • Peña C.
        • Ariza J.
        • Martin R.
        • Gudiol F.
        Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia. A matched case-control study.
        Arch Intern Med. 1993; 153: 1581-1586
        • Donskey C.J.
        The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens.
        Clin Infect Dis. 2004; 39: 219-226
        • Agudelo Higuita N.I.
        • Huycke M.M.
        Enterococcal disease, epidemiology, and implications for treatment.
        in: Gilmore M.S. Clewell D.B. Ike Y. Shankar N. Enterococci: from commensals to leading causes of drug resistant infection. Massachusetts Eye and Ear Infirmary, Boston [MA]2014: 45-70
        • Falagas M.E.
        • Vardakas K.Z.
        Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
        Drug Saf. 2008; 31: 753-768

      CHORUS Manuscript

      View Open Manuscript